Sign In
Buy MLYS
$25.61
+0.240 (+0.95%)
At Close: Jun 23, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc. - MLYS
10:00am, Thursday, 22'nd Aug 2024
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or the "Company") (NASDAQ:MLYS). Such investors
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc. - MLYS
01:30pm, Monday, 19'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or the "Company") (NASDAQ:MLYS). Such investors
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc. - MLYS
10:30pm, Wednesday, 14'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or the "Company") (NASDAQ:MLYS). Such investors
Mineralys Therapeutics, Inc. (MLYS) Q2 2024 Earnings Call Transcript
08:01pm, Tuesday, 13'th Aug 2024
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam L
Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D.
08:00am, Friday, 14'th Jun 2024
Dr. Olivier Litzka has resigned from the Board, effective June 13, 2024 Dr. Olivier Litzka has resigned from the Board, effective June 13, 2024
Mineralys Therapeutics, Inc. (MLYS) Q1 2024 Earnings Call Transcript
02:35pm, Saturday, 11'th May 2024
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Garth Russell – LifeSci Advisors Jon Congleton – Chief Executive Officer Ad
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
07:00am, Thursday, 09'th May 2024
– Advance-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in Q4 2024 –
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
08:00am, Monday, 06'th May 2024
RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ki
Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024
08:00am, Thursday, 02'nd May 2024
RADNOR, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ki
What To Buy After You Sell The Russell 2000
03:07am, Wednesday, 03'rd Apr 2024
What To Buy After You Sell The Russell 2000
Mineralys Therapeutics, Inc. (MLYS) Q4 2023 Earnings Call Transcript
11:48am, Thursday, 21'st Mar 2024
Mineralys Therapeutics, Inc. (MLYS) Q4 2023 Earnings Call Transcript
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
07:00am, Thursday, 21'st Mar 2024
– Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or rHTN is on track, with topline data expected for Advance-HTN trial in Q4 2024 a nd Launch-HTN trial in 2H 2025 –
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024
04:05pm, Wednesday, 13'th Mar 2024
RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic
Mineralys: 2nd Half 2024 Hypertension Data Readout
09:33am, Friday, 09'th Feb 2024
Mineralys: 2nd Half 2024 Hypertension Data Readout
Mineralys Therapeutics Announces $120 Million Private Placement Financing
08:00am, Thursday, 08'th Feb 2024
RADNOR, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic k
